ACA
RLMD icon

American Capital Advisory’s Relmada Therapeutics RLMD Stock Holding History

American Capital Advisory’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5K Hold
1,954
– – ﹤0.01% 330
2026
Q1 		$13.6K Hold
1,954
– – 0.01% 320
2025
Q4 		$9.44K Hold
1,954
– – ﹤0.01% 329
2025
Q3 		$3.93K Hold
1,954
– – ﹤0.01% 366
2025
Q2 		$1.17K Sell
1,954
-1,954
-50% -$1K ﹤0.01% 474
2025
Q1 		$1.06K Buy
3,908
+1,954
+100% +$648 ﹤0.01% 424
2024
Q4 		$1.02K Hold
1,954
– – ﹤0.01% 421
2024
Q3 		$6.33K Buy
1,954
+754
+63% +$2.44K ﹤0.01% 330
2024
Q2 		$4.97K Hold
1,200
– – ﹤0.01% 304
2024
Q1 		$2.71K Hold
1,200
– – ﹤0.01% 351
2023
Q4 		$4.97K Buy
+1,200
New +$3.55K ﹤0.01% 304

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Capital Advisory's RLMD Position: Q2 2026 in Review

American Capital Advisory held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 1,954 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #330.

American Capital Advisory first reported a position in RLMD in Q4 2023 and has held it in 11 quarters since. The position peaked at $13.6K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • American Capital Advisory held 1,954 shares of Relmada Therapeutics worth $13.5K as of Q2 2026.
  • American Capital Advisory left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #330 holding.
  • American Capital Advisory first reported a position in Relmada Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • American Capital Advisory's Relmada Therapeutics position peaked at $13.6K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.